Clinical trial
Sorafenib and RAD001 Renal Cell Carcinoma
NCT00384969 · University of California, San Francisco, Other · Completed
Key facts
| NCT number | NCT00384969 |
|---|---|
| Title | Sorafenib and RAD001 Renal Cell Carcinoma |
| Official title | A Phase I Study of Sorafenib and RAD001 in Patients With Metastatic Renal Cell Carcinoma |
| Lead sponsor | University of California, San Francisco, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | RAD001 and Sorafenib |
| Enrollment | 21 |
| Start date | Oct 1, 2006 |
| Primary completion | Dec 1, 2013 |
| Completion | Mar 1, 2014 |
| First posted | Oct 6, 2006 |
| Last update posted | Aug 18, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: